Hims & Hers HealthHIMS
HIMS
About: Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.
Employees: 1,637
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
228% more first-time investments, than exits
New positions opened: 131 | Existing positions closed: 40
57% more capital invested
Capital invested by funds: $2.52B [Q3] → $3.97B (+$1.45B) [Q4]
28% more funds holding
Funds holding: 304 [Q3] → 389 (+85) [Q4]
27% more repeat investments, than reductions
Existing positions increased: 131 | Existing positions reduced: 103
12.33% more ownership
Funds ownership: 65.82% [Q3] → 78.15% (+12.33%) [Q4]
0% more call options, than puts
Call options by funds: $384M | Put options by funds: $383M
25% less funds holding in top 10
Funds holding in top 10: 8 [Q3] → 6 (-2) [Q4]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$25
30%
downside
Avg. target
$40
11%
upside
High target
$68
90%
upside
9 analyst ratings
2 positive
22%
5 neutral
56%
2 negative
22%
B of A Securities Allen Lutz 69% 1-year accuracy 11 / 16 met price target | 27%downside $26 | Underperform Maintained | 29 Apr 2025 |
Morgan Stanley Craig Hettenbach 33% 1-year accuracy 1 / 3 met price target | 12%upside $40 | Equal-Weight Maintained | 29 Apr 2025 |
TD Cowen Jonna Kim 75% 1-year accuracy 3 / 4 met price target | 16%downside $30 | Hold Downgraded | 29 Apr 2025 |
Citigroup Daniel Grosslight 0 / 0 met price target | 30%downside $25 | Sell Maintained | 25 Apr 2025 |
Truist Securities Jailendra Singh 34% 1-year accuracy 12 / 35 met price target | 8%downside $33 | Hold Maintained | 10 Apr 2025 |
Financial journalist opinion
Based on 49 articles about HIMS published over the past 30 days
Positive
Seeking Alpha
3 hours ago
Hims & Hers: Revolutionizing Healthcare
The company's vertically integrated platform enhances scalability and efficiency, controlling the entire patient experience from consultation to medication delivery. Partnerships, especially with Novo Nordisk for GLP-1 weight-loss drugs, significantly boost revenue and deepen customer relationships. Embracing AI and peptide therapies positions Hims & Hers for future growth, though regulatory compliance and reliance on third-party suppliers pose risks.
Positive
Zacks Investment Research
5 hours ago
4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates
MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release.
Positive
Zacks Investment Research
20 hours ago
Buy Hims (HIMS) or Novo Nordisk (NVO) Stock After Partnership Announcement?
Medical pioneers Hims & Hers Health (HIMS) and Novo Nordisk (NVO) are making headlines this week after announcing a partnership to expand obesity care in the telehealth space.
Positive
Zacks Investment Research
1 day ago
Hims & Hers vs. Teladoc: Which Telehealth Stock Is the Better Buy Now?
Both HIMS and TDOC are technology-intensive healthcare companies that leverage their strengths in the digital health space to enhance their platforms. Which one is a better investment?
Positive
MarketBeat
1 day ago
Hims & Hers Stock Soars on Novo Nordisk Collaboration
Every once in a while, investors come across some of the best names in a given industry, which then become subject to the best news and developments during a holding period. Today's best pick seems to be in the medical sector.
Positive
Fast Company
1 day ago
Hims & Hers stock price soars after partnership with Novo Nordisk to offer weight-loss drug Wegovy
Shares in Hims & Hers Health, Inc. (NYSE: HIMS) are skyrocketing in early-morning trading today after the telehealth company announced a new partnership with the Danish pharmaceutical giant Novo Nordisk. That partnership will see Hims & Hers offer Novo Nordisk's weight-loss drug Wegovy through its platform.
Positive
Zacks Investment Research
1 day ago
Hims & Hers Health (HIMS) Stock Jumps 23.0%: Will It Continue to Soar?
Hims & Hers Health (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Positive
Seeking Alpha
1 day ago
Hims & Hers Health: GLP-1 Deals De-Risk The Story
Hims & Hers Health partners with Novo Nordisk to offer Wegovy, de-risking investment but not significantly altering the business focus on personalized healthcare solutions. The health and wellness platform already targeted $725 million in weight-loss sales this year, without including any branded GLP-1 sales. The company's core business remains robust, with significant contributions from sexual health, dermatology, and mental health, accounting for over $1.2 billion in 2024 sales.
Positive
The Motley Fool
1 day ago
Why Hims & Hers Health and LifeMD Are Skyrocketing Today
Shares of Hims & Hers Health (HIMS 25.46%) and LifeMD (LFMD 35.41%) are surging on Tuesday. The companie' stocks had jumped 24% and 34%, respectively, as of 3:15 p.m.
Positive
Proactive Investors
2 days ago
Hims & Hers stock pops on Novo Nordisk partnership
Hims & Hers (NYSE:HIMS) shares surged after it announced a partnership with Novo Nordisk that will allow it to offer the drugmaker's weight loss product Wegovy through its telehealth platform. Investors welcomed the collaboration, which positions Hims & Hers to participate directly in the fast-growing market for GLP-1 weight-loss drugs.
Charts implemented using Lightweight Charts™